Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
BioNTech SE
Bristol-Myers Squibb
Canadian Cancer Trials Group
AbbVie
Bristol-Myers Squibb
AbbVie
Second Affiliated Hospital of Nanchang University
Pfizer
Rigshospitalet, Denmark
SWOG Cancer Research Network
Cancer Research UK
Hansoh BioMedical R&D Company
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Second Affiliated Hospital of Guangzhou Medical University
Hunan Province Tumor Hospital
Guy's and St Thomas' NHS Foundation Trust
Chang Gung Memorial Hospital